Detalhe da pesquisa
1.
Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec.
Oncologist
; 27(10): 822-831, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830543
2.
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med
; 372(4): 320-30, 2015 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-25399552
3.
DNA methylation signatures of breast cancer in peripheral T-cells.
BMC Cancer
; 18(1): 574, 2018 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29776342
4.
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.
Breast Cancer Res
; 19(1): 54, 2017 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28464908
5.
The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience.
Mod Pathol
; 30(11): 1567-1576, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28752846
6.
Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity.
Commun Biol
; 7(1): 526, 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38702425
7.
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation.
Cancer Discov
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691346
8.
Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.
Am J Cancer Res
; 13(1): 25-44, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36777514
9.
The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.
Genes (Basel)
; 15(1)2023 Dec 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38254917
10.
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.
J Clin Oncol
; 41(1): 75-85, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35867951
11.
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Breast Cancer Res Treat
; 133(1): 217-26, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21915635
12.
Parathyroid Hormone-Related Protein Inhibition Blocks Triple-Negative Breast Cancer Expansion in Bone Through Epithelial to Mesenchymal Transition Reversal.
JBMR Plus
; 6(6): e10587, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35720668
13.
Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors.
Oncoimmunology
; 11(1): 2096535, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35832043
14.
Spatially mapping the immune landscape of melanoma using imaging mass cytometry.
Sci Immunol
; 7(70): eabi5072, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363543
15.
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Nat Med
; 27(8): 1432-1441, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34239137
16.
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
J Immunother Cancer
; 9(10)2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34599031
17.
Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.
Front Oncol
; 10: 1361, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32983966
18.
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer.
Sci Rep
; 10(1): 14704, 2020 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32895401
19.
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma.
J Clin Oncol
; 38(33): 3937-3946, 2020 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32997575
20.
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.
JAMA Oncol
; 5(2): 187-194, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30422243